Real-World Study Shows Pazopanib Outperforms Sunitinib in Advanced Alveolar Soft Part Sarcoma
核心洞察
A multicenter retrospective study of 51 patients with metastatic alveolar soft part sarcoma (搜索) found that pazopanib demonstrated superior outcomes compared to sunitinib in first-line treatment.
Pazopanib showed a trend toward longer progression-free survival (27.2 vs. 15.2 months) and significantly prolonged overall survival (45.0 vs. 21.0 months) versus sunitinib.
First-line tyrosine kinase inhibitor therapy achieved significantly longer median progression-free survival compared with chemotherapy (搜索) (24.9 vs. 5.8 months).
A large real-world study has provided new evidence supporting pazopanib over sunitinib as the preferred first-line treatment for advanced alveolar soft part sarcoma (搜索) (ASPS (搜索)), an ultra-rare and highly angiogenic sarcoma (搜索) with limited treatment options. The multicenter retrospective analysis of 51 patients with metastatic ASPS (搜索) treated between January 2013 and March 2025 represents one of the largest real-world cohorts examining tyrosine kinase inhibitor (TKI) outcomes in this challenging malignancy.
Superior Outcomes with Pazopanib
In first-line comparisons, pazopanib demonstrated clinically meaningful advantages over sunitinib. The study found pazopanib showed a trend toward longer progression-free survival (PFS) with a median of 27.2 months compared to 15.2 months for sunitinib (p = 0.052). More significantly, pazopanib achieved substantially prolonged overall survival (OS) of 45.0 months versus 21.0 months for sunitinib (p = 0.021).
When examining outcomes across all treatment lines, pazopanib maintained its advantage with median PFS and OS of 24.9 and 38.3 months respectively, compared to 17.7 and 21.0 months for sunitinib.
TKIs Outperform Chemotherapy
The study reinforced the superiority of anti-angiogenic therapy over traditional chemotherapy (搜索) in ASPS (搜索). First-line TKI therapy achieved significantly longer median PFS compared with chemotherapy, extending from 5.8 months with chemotherapy to 24.9 months with TKIs (搜索) (p < 0.001). However, this survival advantage did not translate to a significant overall survival difference between the treatment approaches.
Prognostic Factors and Safety Profile
Multivariate analysis identified key prognostic factors that influence treatment outcomes. Prior chemotherapy (搜索) and the presence of liver metastases emerged as independent predictors of shorter progression-free survival, providing clinicians with important considerations for treatment planning and patient counseling.
Both sunitinib and pazopanib demonstrated favorable safety profiles in this patient population. The study reported that both agents were well tolerated, with toxicities predominantly consisting of Grade 1-2 adverse events, making them viable long-term treatment options for patients with this chronic condition.
Clinical Implications for Ultra-Rare Sarcoma
These findings have important implications for the management of ASPS (搜索), a malignancy known for its resistance to conventional cytotoxic chemotherapy (搜索) but recognized sensitivity to anti-angiogenic agents. The study's results reinforce the role of anti-angiogenic therapy as the preferred first-line approach in advanced ASPS, with pazopanib emerging as potentially the optimal choice among available TKIs (搜索).
The researchers emphasized that frontline TKIs (搜索) provided substantial disease control and prolonged survival compared with chemotherapy (搜索), while maintaining manageable toxicity profiles. This real-world evidence supports current treatment paradigms that prioritize anti-angiogenic therapy in the initial management of metastatic ASPS (搜索).
The study authors noted that prospective studies are warranted to optimize treatment sequencing in this ultra-rare sarcoma (搜索), highlighting the ongoing need for clinical research in rare malignancies where randomized controlled trials remain challenging to conduct due to limited patient populations.